Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.

Victoria FurerTali EviatarDevy ZismanHagit PelegDaphna ParanDavid LevartovskyMichael ZisapelOfir ElaloufIlana KaufmanRoni MeidanAdi BroydeAri PolachekJonathan WollmanIra LitinskyKatya MeridorHila NochomovitzAdi SilbermanDana RosenbergJoy FeldAmir HaddadTal GazzitMuna EliasNizar HigaziFadi KharoufGabi SheferOrly SharonSara PelSharon NevoOri Elkayam

Published in: Annals of the rheumatic diseases (2021)

mRNA BNTb262 vaccine was immunogenic in the majority of patients with AIIRD, with an acceptable safety profile. Treatment with glucocorticoids, rituximab, MMF, and abatacept was associated with a significantly reduced BNT162b2-induced immunogenicity.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
drug induced
multiple sclerosis
oxidative stress
diabetic rats
diffuse large b cell lymphoma
high glucose
combination therapy
systemic lupus erythematosus
respiratory syndrome coronavirus